"The
Report PharmaPoint: Dyslipidemia - Global Drug Forecast and Market
Analysis to 2023 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
GlobalData
estimates that the total market size for the 8MM in 2013 was $15.4bn,
comprised of $11.0bn in branded drug sales (72%) and $4.4bn in
generic sales (28%). GlobalData expects that the dyslipidemia drug
market will grow at a CAGR of 9.4% over the ten year forecast period,
resulting in a market value of $37.9bn by 2023, of which 71% will be
attributed to branded drug sales ($26.9bn) and 29% to generic drug
sales ($11.0bn). The current dyslipidemia market is dominated by the
statins, the revolutionary drugs that reduce low-density lipoprotein
cholesterol (LDL-C) and that have been proven to reduce the risk of
cardiovascular events such as heart attack and stroke. Other major
lipid-modulating drugs, such as Zetia (ezetimibe), the fibrates, bile
acid sequestrants, omega-3 fish oil agents, and rare-disease
therapies comprise the remainder of the current dyslipidemia space.
The launch of the proprotein convertase subtilisin/kexin type 9
(PCSK9) biologics and the cholesteryl ester transfer protein (CETP)
inhibitors will reshape the sales landscape of the dyslipidemia
market moving forward.
View Report At
:http://www.marketresearchreports.biz/analysis/308762
Highlights
Key Questions Answered
-
How will major clinical trials of currently marketed therapies impact
the future of the dyslipidemia market? Particular attention will be
given to the HPS2-THRIVE and IMPROVE-IT Phase III studies of niacin
and Zetia (ezetimibe).
-
What role will statins play in the future of the dyslipidemia market?
-
What are the clinical, regulatory, and commercial prospects of the
proprotein convertase subtilisin/kexin type 9 monoclonal antibodies
(PCSK9 mAbs) from Amgen, Sanofi/Regeneron, and Pfizer and the
cholesteryl ester transfer protein (CETP) inhibitors from Eli Lilly,
Merck, and Dezima Pharma?
-
How will novel lipid-modulating agents, such as Esperion Therapeutics
ETC-1002 and Cerenis Therapeutics CER-001, impact the dynamics of the
dyslipidemia market?
-
What are the key market drivers, barriers, and unmet needs that
remain unaddressed by currently marketed therapies? What will remain
unaddressed by the current dyslipidemia pipeline?
Key Findings
-
The highest-impact driver of the dyslipidemia market will be the
launch of the PCSK9 inhibitors, human monoclonal antibody biologics
that will be used to treat high LDL-C in addition to statins.
Therapeutic novelty combined with biologic pricing will make the
PCSK9s the largest contributors to dyslipidemia market growth, even
if their use is reserved for niche or high-risk cases.
-
The CETP inhibitors in the late-stage pipeline have the potential to
bring a novel tool to bear against high LDL-C and low HDL-C. However,
their success at the regulatory level will depend heavily on their
success in major Phase III cardiovascular outcomes trials, making the
CETPs the wild-cards of the dyslipidemia pipeline.
-
Due to the maturity of the current dyslipidemia market, new therapies
will need to exploit novel mechanisms of action and/or target orphan
drug targets and are more likely to be utilized as add-on therapies
to existing treatments. There is a unique opportunity in the familial
hypercholesterolemia arena, where effective LDL-C lowering therapies
are needed that exhibit clean safety/side-effect profiles.
Download
Sample copy of this Report at:
http://www.marketresearchreports.biz/sample/sample/308762
Scope
-
Overview of dyslipidemia, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
-
Annualized dyslipidemia therapeutics market revenue, annual cost of
therapy and treatment usage pattern data from 2013 and forecast for
ten years to 2023.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping, and
implications for the dyslipidemia therapeutics market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
late-stage pipeline drugs.
-
Analysis of the current and future market competition in the global
dyslipidemia therapeutics market. Insightful review of the key
industry drivers, restraints and challenges. Each trend is
independently researched to provide qualitative analysis of its
implications.
Reasons to buy
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the dyslipidemia therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
dyslipidemia therapeutics market in the future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the 8MM dyslipidemia therapeutics market from
2013-2023.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment